DWDavid Williams

David Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Williams has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Postpartum diagnosis of pheochromocytoma presenting as atypical hypertensive disorder of pregnancy: A case report

    by Lakshya Sharma, Bernard Khoo, David Williams, Vinita Singh

    Introduction: Pheochromocytoma, a catecholamine-secreting adrenal tumour, is a rare but important cause of hypertension in pregnancy. Its symptoms may mimic more common disorders of pregnancy, making diagnosis challenging. We present a postpartum pheochromocytoma diagnosis with favourable maternal and neonatal outcomes. Case presentation: A 29-year-old woman in her first pregnancy developed proteinuria at 34 weeks and new-onset hypertension at 36 weeks, managed as pre-eclampsia. Worsening hypertension, gestational diabetes and breech presentation led to caesarean section at 36 weeks and 4 days of gestation. Postpartum, she experienced severe headaches, labile blood pressure, tachycardia and sweating. Imaging identified a 4 cm right adrenal mass. Markedly elevated plasma and urinary normetanephrines confirmed pheochromocytoma. Right adrenalectomy was performed seven weeks post-partum, with complete excision. Symptoms resolved postoperatively. Subsequent surveillance imaging showed no recurrence. She later had a second uncomplicated pregnancy. Conclusion: This case highlights how pheochromocytoma in pregnancy can be differentiated from more common conditions. Prompt diagnosis and multidisciplinary management can optimise patient outcomes.

  • Placental Enterovirus Infection Is Not Evident in Chronic Histiocytic Intervillositis

    by Emily F. Cornish, Alexander Lennon, Julianne R. Brown, James Burton, Olumide Ogunbiyi, Theodoros Xenakis, Yara Sanchez Corrales, J. C. Hutchinson, David J. Williams

    Was not provided for this article.

  • Open Access

    Severe, uncontrolled epilepsy in pregnancy: A population-based case-control study

    by Bryn Kemp, Andrew Kelso, David Williams, Marian Knight

    Background Epilepsy affects one percent of the UK population and is the most common serious neurological condition experienced during pregnancy. We compared the characteristics, clinical management, and pregnancy outcomes in women with severe, uncontrolled epilepsy to those of women with well controlled disease. Methods We conducted a population-based case-control study in all UK consultant-led maternity units. Cases of severe uncontrolled epilepsy during pregnancy were identified prospectively and reported via the UK Obstetric Surveillance System (UKOSS). Severe epilepsy was defined a-priori as ≥1 of the following: admission to hospital during pregnancy to manage seizures; prescribed ≥3 antiepileptic medications; or died from epilepsy. Controls comprised women with epilepsy not meeting the case definition, identified within the same centres as cases. Pre-pregnancy epilepsy control and pregnancy outcomes were compared between groups using multivariable logistic regression. Results We identified 94 cases between 1 October 2015 and 31 March 2017 and compared these with 186 controls. Cases were significantly more likely to be admitted to manage seizures in the year preceding pregnancy (42/94 cases vs 10/186 controls, adjusted odds ratio [aOR]=7.38 [95% CI 2.70-20.2]), and to report their most recent seizure within 3 months of pregnancy (51/94 cases vs 18/186 controls, aOR=5.86 [95% CI 2.30-15.0]). Cases were significantly more likely to deliver before 37 weeks (20/94 cases vs 8/186 controls, aOR=7.61 [95% CI 2.87-20.2]). Conclusions Women admitted for seizure management in the year before pregnancy are at higher risk of severe epilepsy during pregnancy and of preterm birth. These women should be prioritised for discussion about pregnancy and contraception. When pregnant, they should be reviewed as early as possible by specialists in the management of epilepsy during pregnancy. Delivering messages about the importance of pregnancy planning and contraception to all women with epilepsy should be viewed as the responsibility of all clinicians involved their care.


  • Open Access

    Use of sodium valproate and other antiseizure drug treatments in England and Wales: quantitative analysis of nationwide linked electronic health records

    by Caroline E Dale, Rohan Takhar, Yat Yi Fan, Fatemeh Torabi, Michail Katsoulis, Samuel Kim, Andrew Lambarth, Christopher Tomlinson, Tim Wilkinson, Tanja Mueller, et al.

    Objective: To investigate the use of sodium valproate in England and Wales, including during pregnancy, compared with other antiseizure drug treatments, based on national level electronic health records. Design: Quantitative analysis of nationwide linked electronic health records. Setting: Individual level, population scale data from NHS England's Secure Data Environment, from the British Heart Foundation Data Science Centre's CVD-COVID-UK/COVID-IMPACT Consortium (for England), and the Secure Anonymised Information Linkage Databank (for Wales), 1 January 2019 to 31 December 2023. Participants: 1 200 000 individuals dispensed any selected antiseizure drug treatment (ie, sodium valproate, lamotrigine, levetiracetam, carbamazepine, or topiramate); 304 000 women, aged 15-49 years, dispensed any selected antiseizure drug treatment and 28 400 women, aged 15-49 years, dispensed sodium valproate. Main outcome measures: Prevalent (current) and incident (new) uses of sodium valproate and other antiseizure drug treatments before and during the covid-19 pandemic (1 January 2019 to 31 December 2023), grouped by age and sex. Pregnancy rates per 1000 women, aged 15-49 years, who used antiseizure drug treatments, and timing and dose of sodium valproate dispensed during pregnancy. Geographical variation in use of sodium valproate and disease indications (epilepsy and bipolar affective disorder). Trends in deaths related to epilepsy for 2015-22. Results: Prevalent use of sodium valproate in women of childbearing potential decreased and use of most other antiseizure drug treatments increased between 2019 and 2023. Incident use of sodium valproate per 100 000 women decreased from seven to five in women aged 15-19 years, from 11 to seven in women aged 20-29 years, and from 14 to seven in women aged 30-39 years between 2019 and 2022. Incident use also decreased in men of the same age but remained at much higher levels (from 53 to 43 in men aged 15-19 years, 59 to 47 in men aged 20-29 years, and 57 to 42 in men aged 30-39 years, per 100 000 men). Pregnancy rates decreased from 6.0 to 5.2 per 1000 women of childbearing potential who were dispensed sodium valproate over the same period. The number of pregnant women who used sodium valproate during pregnancy decreased from 140 in 2019 to 85 in 2023. Epilepsy was the most common indication, followed by bipolar affective disorder (751 and 193 per 1000 women of childbearing potential dispensed sodium valproate, respectively, in 2023). No clear evidence was found that deaths related to epilepsy increased in women aged 15-49 during 2015-22, but a slight increase was found in men aged 15-49 during the later period between April 2018 and December 2022. Conclusions: Based on comprehensive national records, changes in the dispensing of antiseizure drug treatments in response to regulatory actions were tracked. Rates for use of sodium valproate by women, including during pregnancy, decreased before and continued to slowly decrease during the covid-19 pandemic. Incident use was also reduced in men but remained at much higher levels than in women. This approach, linking national dispensing data to health records at the individual level, could help monitor changes to medicines affected by regulatory changes, including in specific population groups, such as pregnant individuals, and their potential effect on health outcomes.


  • Open Access

    Severe, uncontrolled epilepsy in pregnancy: A population-based case-control study

    by Bryn Kemp, Andrew Kelso, David Williams, Marian Knight

    Background Epilepsy affects one percent of the UK population and is the most common serious neurological condition experienced during pregnancy. We compared the characteristics, clinical management, and pregnancy outcomes in women with severe, uncontrolled epilepsy to those of women with well controlled disease. Methods We conducted a population-based case-control study in all UK consultant-led maternity units. Cases of severe uncontrolled epilepsy during pregnancy were identified prospectively and reported via the UK Obstetric Surveillance System (UKOSS). Severe epilepsy was defined a-priori as ≥1 of the following: admission to hospital during pregnancy to manage seizures; prescribed ≥3 antiepileptic medications; or died from epilepsy. Controls comprised women with epilepsy not meeting the case definition, identified within the same centres as cases. Pre-pregnancy epilepsy control and pregnancy outcomes were compared between groups using multivariable logistic regression. Results We identified 94 cases between 1 October 2015 and 31 March 2017 and compared these with 186 controls. Cases were significantly more likely to be admitted to manage seizures in the year preceding pregnancy (42/94 cases vs 10/186 controls, adjusted odds ratio [aOR]=7.38 [95% CI 2.70-20.2]), and to report their most recent seizure within 3 months of pregnancy (51/94 cases vs 18/186 controls, aOR=5.86 [95% CI 2.30-15.0]). Cases were significantly more likely to deliver before 37 weeks (20/94 cases vs 8/186 controls, aOR=7.61 [95% CI 2.87-20.2]). Conclusions Women admitted for seizure management in the year before pregnancy are at higher risk of severe epilepsy during pregnancy and of preterm birth. These women should be prioritised for discussion about pregnancy and contraception. When pregnant, they should be reviewed as early as possible by specialists in the management of epilepsy during pregnancy. Delivering messages about the importance of pregnancy planning and contraception to all women with epilepsy should be viewed as the responsibility of all clinicians involved their care.

  • Open Access

    Ribosomal DNA copy number is associated with body mass in humans and other mammals

    by Pui Pik Law, Liudmila A. Mikheeva, Francisco Rodriguez-Algarra, Fredrika Asenius, Maria Gregori, Robert A. E. Seaborne, Selin Yildizoglu, James R. C. Miller, Hemanth Tummala, Robin Mesnage, et al.

    Body mass results from a complex interplay between genetics and environment. Previous studies of the genetic contribution to body mass have excluded repetitive regions due to the technical limitations of platforms used for population scale studies. Here we apply genome-wide approaches, identifying an association between adult body mass and the copy number (CN) of 47S-ribosomal DNA (rDNA). rDNA codes for the 18 S, 5.8 S and 28 S ribosomal RNA (rRNA) components of the ribosome. In mammals, there are hundreds of copies of these genes. Inter-individual variation in the rDNA CN has not previously been associated with a mammalian phenotype. Here, we show that rDNA CN variation associates with post-pubertal growth rate in rats and body mass index in adult humans. rDNA CN is not associated with rRNA transcription rates in adult tissues, suggesting the mechanistic link occurs earlier in development. This aligns with the observation that the association emerges by early adulthood.


  • Open Access

    Stillbirths due to placental COVID infection associated with chronic histiocytic intervillositis do not recur in subsequent pregnancies

    by Emily F. Cornish, Lotte E. van der Meeren, Marie-Louise P. van der Hoorn, Sam Schoenmakers, Alexandre J. Vivanti, Alexandra Benachi, Melissa Whitten, Stephanie Hignett, Thomas McDonnell, David J. Williams


  • Open Access

    Gestational surrogacy for women with recurrent pregnancy loss due to refractory chronic histiocytic intervillositis

    by Emily F. Cornish, Claudia A. A. Belardo, Roger Turnell, Thomas McDonnell, David J. Williams


  • Open Access

    Uric acid and risk of pre-eclampsia: results from a large case–control study and meta-analysis of prospective studies

    by Claudia C. Colmenares-Mejia, Doris C. Quintero-Lesmes, Paula K. Bautista-Niño, Elizabeth Guío, Maria C. Paez, Mónica Beltrán, David Williams, Kathryn J. Gray, Juan P. Casas, Norma C. Serrano

    To quantify the association between maternal uric acid levels and pre-eclampsia risk in a large collection of primigravid women. A case–control study (1365 cases of pre-eclampsia and 1886 normotensive controls) was conducted. Pre-eclampsia was defined as blood pressure ≥ 140/90 mmHg and proteinuria ≥ 300 mg/24 h. Sub-outcome analysis included early, intermediate, and late pre-eclampsia. Multivariable analysis for pre-eclampsia and its sub-outcomes was conducted using binary and multinomial logistic regression, respectively. Additionally, a systematic review and meta-analysis of cohort studies measuring uric acid levels < 20 weeks of gestation was performed to rule out reverse causation. There was a positive linear association between increasing uric acid levels and presence of pre-eclampsia. Adjusted odds ratio of pre-eclampsia was 1.21 (95%CI 1.11–1.33) for every one standard deviation increase in uric acid levels. No differences in the magnitude of association were observed between early and late pre-eclampsia. Three studies with uric acid measured < 20 weeks’ gestation were identified, with a pooled OR for pre-eclampsia of 1.46 (95%CI 1.22–1.75) for a top vs. bottom quartile comparison. Maternal uric acid levels are associated with risk of pre-eclampsia. Mendelian randomisation studies would be helpful to further explore the causal role of uric acid in pre-eclampsia.